Monte Rosa [GLUE] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Monte Rosa Therapeutics Inc. wins in 10 metrics, Zymeworks Inc. wins in 8 metrics, with 0 ties. Monte Rosa Therapeutics Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Monte Rosa Therapeutics Inc. | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 49.22 | 3.79 | Zymeworks Inc. |
| Price-to-Book Ratio | 5.67 | 7.32 | Monte Rosa Therapeutics Inc. |
| Debt-to-Equity Ratio | 16.82 | 6.80 | Zymeworks Inc. |
| PEG Ratio | -0.12 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | -27.83 | -20.40 | Zymeworks Inc. |
| Profit Margin (TTM) | -31.23% | -76.56% | Monte Rosa Therapeutics Inc. |
| Operating Margin (TTM) | -1,787.67% | -1,755.55% | Zymeworks Inc. |
| Return on Equity | -16.94% | -26.72% | Monte Rosa Therapeutics Inc. |
| Return on Assets (TTM) | -7.64% | -14.29% | Monte Rosa Therapeutics Inc. |
| Free Cash Flow (TTM) | $-27.50M | $-35.36M | Monte Rosa Therapeutics Inc. |
| 1-Year Return | 371.53% | 119.86% | Monte Rosa Therapeutics Inc. |
| Price-to-Sales Ratio (TTM) | 13.05 | 18.46 | Monte Rosa Therapeutics Inc. |
| Enterprise Value | $1.28B | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | 10.32 | 16.33 | Monte Rosa Therapeutics Inc. |
| Revenue per Share (TTM) | $1 | $1 | Monte Rosa Therapeutics Inc. |
| Earnings per Share (Diluted) | $-0.46 | $-1.08 | Monte Rosa Therapeutics Inc. |
| Beta (Stock Volatility) | 1.64 | 1.20 | Zymeworks Inc. |
| Short % of Float | 20.65% | 8.16% | Zymeworks Inc. |
Monte Rosa Therapeutics Inc. vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc. | -0.85% | -8.24% | -10.12% | -2.06% | 4.33% | 14.89% |
| Zymeworks Inc. | 1.00% | -1.77% | -9.07% | -0.41% | -7.13% | -8.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc. | 371.53% | 160.71% | 4.51% | 4.51% | 4.51% | 4.51% |
| Zymeworks Inc. | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
Performance & Financial Health Analysis: Monte Rosa Therapeutics Inc. vs Zymeworks Inc.
| Metric | GLUE | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $1.61B | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 947,771 | 626,460 |
| 90 Day Avg. Volume | 1,225,390 | 729,503 |
| Last Close | $17.59 | $24.35 |
| 52 Week Range | $4.12 - $25.77 | $11.51 - $29.75 |
| % from 52W High | -31.74% | -18.15% |
| All-Time High | $45.56 (Sep 06, 2021) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -61.39% | -58.75% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.95% | -0.92% |
| Quarterly Earnings Growth | -0.95% | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | -0.77% |
| Operating Margin (TTM) | -17.88% | -17.56% |
| Return on Equity (TTM) | -0.17% | -0.27% |
| Debt to Equity (MRQ) | 16.82 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.56 | $3.60 |
| Cash per Share (MRQ) | $4.71 | $3.10 |
| Operating Cash Flow (TTM) | $-22,798,000 | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $-129,076,000 | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Monte Rosa Therapeutics Inc. vs Zymeworks Inc.
| Metric | GLUE (Apr 24, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 49.22 | 3.79 |
| Forward P/E | -11.86 | 33.43 |
| PEG Ratio | -0.12 | 0.05 |
| Price to Sales (TTM) | 13.05 | 18.46 |
| Price to Book (MRQ) | 5.67 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $1.61B | $1.96B |
| Enterprise Value | $1.28B | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.32 | 16.33 |
| Enterprise to EBITDA | -27.83 | -20.40 |
| Risk & Other Metrics | ||
| Beta | 1.64 | 1.20 |
| Book Value per Share (MRQ) | $3.56 | $3.60 |
Financial Statements Comparison: Monte Rosa Therapeutics Inc. vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GLUE (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 123.67M | 105.97M |
| Cost of Goods Sold | N/A | N/A |
| COGS % of Revenue | 0.0% | 0.0% |
| Gross Profit | N/A | N/A |
| Gross Margin | 0.0% | 0.0% |
| Research & Development | 141.50M | 137.00M |
| Operating Income (EBIT) | -54.21M | -92.54M |
| Operating Margin | -43.8% | -87.3% |
| EBITDA | -47.40M | -80.82M |
| EBITDA Margin | -38.3% | -76.3% |
| Pre-Tax Income | -39.72M | -79.75M |
| Pre-Tax Income % of Revenue | -32.1% | -75.3% |
| Income Tax | -1.10M | 1.38M |
| Income Tax % of Revenue | -0.9% | 1.3% |
| Net Income (Profit) | -38.63M | -81.13M |
| Profit Margin | -31.2% | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | GLUE (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 129.88M | 41.16M |
| Total Current Assets | 393.19M | 248.77M |
| Total Current Assets % of Revenue | 317.9% | 234.8% |
| Total Current Liabilities | 64.21M | 42.32M |
| Total Current Liabilities % of Revenue | 51.9% | 39.9% |
| Long-Term Debt | 34.79M | 14.80M |
| Long-Term Debt % of Revenue | 28.1% | 14.0% |
| Total Shareholders Equity | 233.06M | 268.50M |
| Retained Earnings | -477.21M | -953.16M |
| Retained Earnings % of Revenue | -385.9% | -899.5% |
| Property, Plant & Equipment | 51.41M | 29.56M |
Cash Flow Statement Comparison
| Metric | GLUE (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | -29.05M | -40.00M |
| Operating Cash Flow % of Revenue | -23.5% | -37.7% |
| Capital Expenditures | -4.70M | -1.52M |
| Free Cash Flow | -27.50M | -35.36M |
| FCF Margin | -22.2% | -33.4% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | -357,000 | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | GLUE | ZYME |
|---|---|---|
| Shares Short | 13.40M | 4.08M |
| Short Ratio | 10.82 | 5.42 |
| Short % of Float | 20.65% | 8.16% |
| Shares Outstanding | 65.54M | 75.19M |
| Float Shares | 57.20M | 72.80M |
| % Held by Insiders | 0.74% | 1.26% |
| % Held by Institutions | 87.50% | 98.45% |
| % Held by Public | 11.76% | 0.29% |
Dividend Analysis & Yield Comparison: Monte Rosa Therapeutics Inc. vs Zymeworks Inc.
| Metric | GLUE | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |